Provided by Tiger Trade Technology Pte. Ltd.

Assembly Biosciences

28.08
-0.5000-1.75%
Volume:36.64K
Turnover:1.02M
Market Cap:444.15M
PE:-51.42
High:28.18
Open:28.10
Low:27.59
Close:28.58
52wk High:39.71
52wk Low:7.75
Shares:15.82M
Float Shares:7.55M
Volume Ratio:0.71
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5461
EPS(LYR):-0.5461
ROE:-5.10%
ROA:-4.02%
PB:2.15
PE(LYR):-51.42

Loading ...

Assembly Biosciences Advances HSV-2 Drug ABI-1179 With Completion of Early-Stage Trial

TIPRANKS
·
Yesterday

Assembly Biosciences (ASMB) Quarterly Profit Of US$22.1 Million Tests Bearish Narratives

Simply Wall St.
·
Mar 21

Assembly Biosciences Files $400 Million Mixed Shelf

MT Newswires Live
·
Mar 20

Assembly Biosciences files $400M mixed securities shelf

TIPRANKS
·
Mar 20

Assembly Biosciences Q4 EPS $1.30 Beats $(0.65) Estimate, Sales $42.469M Beat $7.423M Estimate

Benzinga
·
Mar 20

Assembly Biosciences FY 2025 net loss narrows to USD 6.12 million as collaboration revenue rises 100% to USD 72.3 million

Reuters
·
Mar 20

Assembly Biosciences FY EPS USD -0.55

THOMSON REUTERS
·
Mar 20

Press Release: Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights

Dow Jones
·
Mar 20

U.S. Earnings Preview: After Market Close March 18

Dow Jones
·
Mar 19

Assembly Biosciences Inc expected to post a loss of 65 cents a share - Earnings Preview

Reuters
·
Mar 17

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 05

Some Confidence Is Lacking In Assembly Biosciences, Inc. (NASDAQ:ASMB) As Shares Slide 27%

Simply Wall St.
·
Jan 22

BUZZ-Assembly Biosciences rises as Gilead opts to license co's HSV therapies

Reuters
·
Dec 23, 2025

Assembly Biosciences Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 23, 2025

BRIEF-Gilead Sciences Exercises Option To License Assembly Biosciences’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes

Reuters
·
Dec 22, 2025

Gilead - Assembly Bio to Receive $35 Mln for Gilead's Hsv Option

THOMSON REUTERS
·
Dec 22, 2025

U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer

Reuters
·
Dec 10, 2025

Assembly Biosciences Reports Interim Phase 1b Data Showing Reductions in HSV-2 Shedding and Lesion Rates

MT Newswires Live
·
Dec 09, 2025

Assembly Biosciences Reports Positive Interim Results From Phase 1B Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates Abi-1179 and Abi-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

THOMSON REUTERS
·
Dec 09, 2025

Assembly Biosciences Reports Positive Phase 1b Results for Long-Acting HSV Inhibitors ABI-1179 and ABI-5366

Reuters
·
Dec 09, 2025